Ajanta Pharma reports 12% yoy growth in revenue; stock ends up over 3%

31 Jan 2022 , 04:50 PM

In its press release on Monday, Ajanta Pharma Ltd. announced its results for the quarter ending December 2021 and reported a 12% rise in its revenue. Its revenue for the quarter stood at Rs 838 crore against Rs 749 crore for the previous corresponding quarter. Its revenue for the 9M period ended December 2021 stood at Rs 2,471 crore against Rs 2,133 crore, reflecting a growth of 16% YoY.

The company’s EBITDA stood at Rs 240 crore for Q3 FY’22 against Rs 242 crore for Q3 FY’21, down by 0.83% YoY. While its EBITDA margin stood at 29%. Its EBITDA for the 9M period ending December 2021 stood at Rs 731 crore against Rs 739 crore for the previous corresponding period, down by 1.08% YoY.

Company reported a PAT of Rs 192 crore for Q3 FY’22 against Rs 177 crore for Q3 FY’21, up by 9%. While its PAT margin remained at 23% for the quarter. Company reported PAT for the 9M period ending December 2021 at Rs 561 crore against Rs 495 crore for the previous 9M period, up by 14% YoY.

The company reported that its emerging market branded generic sale was Rs. 1,002 cr. against (Rs. 851 cr.) posting 18% growth. Out of which — Asia branded sale stood at Rs 551 crore, posting growth of 3% YoY, and Africa branded sales reported at Rs 451 crore, up by 44% YoY. While US generic sale stood at Rs 528 crore against Rs 464 crore, posting growth of 14%.

The company reported a growth of 7% in Q3 FY 2022 as its total export sales stood at Rs. 563 cr. against Rs. 524 cr.

Ajanta Pharma closed at Rs 2,250 against its previous closing price of Rs 2,177.85, up by Rs 72.15 or 3.31%. It has touched an intraday high and low of Rs 2,250 and Rs 2,140 respectively.